Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Aditya Bardia, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Hope S. Rugo, Adam Brufsky, Kevin Kalinsky, Javier Cortes, Joyce O'Shaughnessy, Veronique C Dieras, Lisa A. Carey, Luca Gianni, Martine J. Piccart-Gebhart, Sibylle Loibl, Yanni Zhu, See-Chun Phan, Sara A. Hurvitz
Institutions: Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Institut Curie, Universitair Ziekenhuis Leuven, Vall d'Hebron Institute of Oncology, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of Pittsburgh Medical Center, Emory University, Winship Cancer Institute, Baylor University Medical Center, The US Oncology Network, Centre Eugène Marquis, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Université Libre de Bruxelles, Institut Jules Bordet, Gilead Sciences (United States), University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
Funder: Gilead Sciences
OpenAlex ID: W4281895526